Thank you for your interest in this edition of Medicom’s Conference Report covering the annual Heart Failure Congress of the Heart Failure Association of the European Society of Cardiology that took place in Madrid, Spain in May 2022. This year’s meeting was filled with late-breaking clinical trials, innovative science and therapeutic device applications for heart failure patients.
In the following pages, you can read about outcomes from the latest clinical trials, including data for Omecamtiv mecarbil, Vutrisiran, Dapagliflozin and Finerenone in patients with heart failure. Also included are results from early phase investigations of novel therapies and mechanisms including cardiac contractility modulation therapy and splanchnic nerve ablation. In addition, there is a dedicated section focused on SGLT2 inhibitors and the broad learnings to date in the care of patients with heart failure. You will also find sections dedicated to novel therapeutic and diagnostic targets and thought-provoking links between cardiac wasting and cancer. As always, our summaries are written independently and are peer-reviewed for balance. We hope you find this edition informative, engaging, and balanced and thank you again for your readership.
Sincerely,
Marc
Biography
Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.
Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.
Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.
Conflict of Interest Statement:
Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi
Posted on
Previous Article
« GALACTIC-HF: Omecamtiv mecarbil as option for HFrEF patients with low SBP Next Article
7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups »
« GALACTIC-HF: Omecamtiv mecarbil as option for HFrEF patients with low SBP Next Article
7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups »
Table of Contents: HFA 2022
Featured articles
Phase 3 and 4 Trials
GALACTIC-HF: Omecamtiv mecarbil as option for HFrEF patients with low SBP
HELIOS-A: Vutrisiran meets exploratory endpoints
Patiromer helps HFrEF patients to optimise RAAS inhibitors without hyperkalaemia
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status
DAPA-VO2: Rapid effect of dapagliflozin on peak VO2 in stable HFrEF
Phase 1/2 Trials
Significant improvement in BP from istaroxime, a novel non-adrenergic agent
SERENADE: Macitentan fails in HFpEF plus PAH
Combination of filgrastim and dutogliptin appears safe in STEMI
Therapeutic Devices
Cardiac contractility modulation therapy promising for patients with HFpEF
REBALANCE-HF: Encouraging observations for splanchnic nerve ablation in HFpEF
Updates on SGLT2 Inhibitors
DAPA-HF: Dapagliflozin is safe and efficacious in frail patients
EMPEROR-Preserved: Empagliflozin stable across age groups
EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion
Dapagliflozin performs consistently across LVEF in HF
Miscellaneous Topics
Cardiac wasting relevant for clinical outcomes in cancer
Urocortin-2 a potential treatment target for HFpEF
Should ATTR-CM be added to the differential diagnosis of patients with HF?
Delayed initiation of novel GDMTs associated with adverse outcomes in HF patients
Related Articles
February 26, 2020
ISCHEMIA trial: Invasive treatment only better for angina burden
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy